MICROBIA Appoints Bart Henderson Vice President, Business Development

Apr 18, 2001, 01:00 ET from MICROBIA, Inc.

    CAMBRIDGE, Mass., April 18 /PRNewswire/ -- MICROBIA, Inc. today announced
 the appointment of Bart Henderson to the newly created position of Vice
 President, Business Development.  Mr. Henderson joins the Company from Vertex
 Pharmaceuticals, Inc. where he was head of Marketing and Sales.  At MICROBIA,
 Mr. Henderson will be responsible for business strategy, marketing the
 Company's proprietary microbial yield improvement technologies, and partnering
 selected anti-biofilm and anti-fungal product development programs.
     Previously, Mr. Henderson held marketing positions at Amgen (Neupogen(R))
 and Merck (Primaxin(R)).  He earned an MBA from The Amos Tuck School at
 Dartmouth, and a BA from Amherst College.
     "Mr. Henderson's fourteen years of business development and marketing
 experience at Vertex, Amgen and Merck make him ideally suited to spearhead
 MICROBIA's efforts to maximize the value of our broad technology platforms by
 complementing internal product development with collaborative relationships
 with pharmaceutical and industrial companies," said Peter Hecht, Chief
 Executive Officer of MICROBIA.
     MICROBIA is a privately held company developing anti-microbial drugs and
 microbial production technologies based on proprietary knowledge of the
 physiological changes made by microbes as they sense and adapt to changes in
 their environment.  The Company's initial priorities are the development of
 biofilm inhibitors and anti-fungal drugs; and a portfolio of technologies to
 enhance the production of microbially-produced drugs and other metabolites.
 $32.8 million of equity capital has been raised to date from investors
 including BancBoston Ventures, Essex Investment Management Company, Venrock
 Associates, Polaris Venture Partners, Aberdare Ventures, and numerous
 individual investors.
 
 

SOURCE MICROBIA, Inc.
    CAMBRIDGE, Mass., April 18 /PRNewswire/ -- MICROBIA, Inc. today announced
 the appointment of Bart Henderson to the newly created position of Vice
 President, Business Development.  Mr. Henderson joins the Company from Vertex
 Pharmaceuticals, Inc. where he was head of Marketing and Sales.  At MICROBIA,
 Mr. Henderson will be responsible for business strategy, marketing the
 Company's proprietary microbial yield improvement technologies, and partnering
 selected anti-biofilm and anti-fungal product development programs.
     Previously, Mr. Henderson held marketing positions at Amgen (Neupogen(R))
 and Merck (Primaxin(R)).  He earned an MBA from The Amos Tuck School at
 Dartmouth, and a BA from Amherst College.
     "Mr. Henderson's fourteen years of business development and marketing
 experience at Vertex, Amgen and Merck make him ideally suited to spearhead
 MICROBIA's efforts to maximize the value of our broad technology platforms by
 complementing internal product development with collaborative relationships
 with pharmaceutical and industrial companies," said Peter Hecht, Chief
 Executive Officer of MICROBIA.
     MICROBIA is a privately held company developing anti-microbial drugs and
 microbial production technologies based on proprietary knowledge of the
 physiological changes made by microbes as they sense and adapt to changes in
 their environment.  The Company's initial priorities are the development of
 biofilm inhibitors and anti-fungal drugs; and a portfolio of technologies to
 enhance the production of microbially-produced drugs and other metabolites.
 $32.8 million of equity capital has been raised to date from investors
 including BancBoston Ventures, Essex Investment Management Company, Venrock
 Associates, Polaris Venture Partners, Aberdare Ventures, and numerous
 individual investors.
 
 SOURCE  MICROBIA, Inc.